Monte Rosa Therapeutics (NASDAQ:GLUE) reported encouraging early clinical results for its molecular glue degrader MRT-2359 in combination with enzalutamide, showing pronounced activity in a genetically defined subset of heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
Updated data from the ongoing study, covering 20 enrolled patients as of Dec. 3, underscore a striking response pattern among those harboring androgen receptor (AR) mutations.
Of the 14 patients evaluable by RECIST criteria, four had AR-mutant disease—a subgroup that posted a 100% prostate-specific antigen (PSA) response rate, including two PSA90 responses.
All four also achieved disease control, with two confirmed RECIST responses, highlighting the potential for MRT-2359 to address resistance mechanisms common in advanced prostate cancer.
Across the broader RECIST-evaluable population, disease control reached 64% (9 of 14 patients).
Meanwhile, safety remained manageable, dominated by Grade 1–2 gastrointestinal events consistent with earlier clinical experience for MRT-2359.